Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...
Zacks Investment Research on MSN1d
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of ...
Pharmaceutical Technology on MSN1d
FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.
Analysts Set Sanofi (NASDAQ:SNY) PT at $60.00
Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...
Sanofi Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer ...
Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review for the regulatory submission of tolebrutinib ...
Rolls-Royce CEO fired managers and held staff brainstorms as part of a ‘4 pillar’ turnaround plan that led to 500% share price jump
Tufan Erginbilgiç's four pillars involved showing employees the extent of Rolls-Royce's issues, then giving them a say in ...
Sanofi Availability of the Q1 2025 Aide mémoire
Aide mémoire Paris, France - March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First ...